Quanterix and Innovita Secure China NMPA Approvals for Neurology…

Event summary

Quanterix and Innovita received NMPA approval for HD-X and SR-X instruments and four neurology biomarker testing kits in China.
Approved biomarkers include p-Tau 217, GFAP, p-Tau 181, and NfL, targeting Alzheimer’s disease and neurodegeneration.
Innovita plans additional regulatory submissions for more Quanterix biomarker diagnostic kits in China.
The partnership combines Quanterix’s SIMOA® technology with Innovita’s diagnostics development and commercialization capabilities.

The big picture

This regulatory milestone strengthens Quanterix’s foothold in China’s growing diagnostics market, where demand for early Alzheimer’s detection is rising. The partnership aligns with global trends toward blood-based biomarker testing, positioning Quanterix to capitalize on the shift toward precision neurology diagnostics. The approvals also underscore Innovita’s role as a key regional partner for expanding access to advanced diagnostic technologies.

What we're watching

Market Expansion: The pace at which Quanterix and Innovita can expand SIMOA-powered diagnostics beyond Alzheimer’s into other neurodegenerative and infectious diseases.
Regulatory Momentum: Whether Innovita can secure additional NMPA approvals for more Quanterix biomarker diagnostic kits in China.
Clinical Integration: How quickly Innovita can integrate SIMOA-powered biomarker testing into routine clinical practice in China.